HK1158631A1 - 橋接的哌嗪基 -烷酮衍生物及其作為 抑制劑的用途 - Google Patents

橋接的哌嗪基 -烷酮衍生物及其作為 抑制劑的用途

Info

Publication number
HK1158631A1
HK1158631A1 HK11112930.5A HK11112930A HK1158631A1 HK 1158631 A1 HK1158631 A1 HK 1158631A1 HK 11112930 A HK11112930 A HK 11112930A HK 1158631 A1 HK1158631 A1 HK 1158631A1
Authority
HK
Hong Kong
Prior art keywords
alkanone
inhibitors
derivatives
bridged piperazinyl
piperazinyl
Prior art date
Application number
HK11112930.5A
Other languages
English (en)
Inventor
Marco Baroni
Franoise Bono
Sandrine Delbary-Gossart
Original Assignee
賽諾菲-安萬特
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賽諾菲-安萬特 filed Critical 賽諾菲-安萬特
Publication of HK1158631A1 publication Critical patent/HK1158631A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK11112930.5A 2008-06-13 2011-11-29 橋接的哌嗪基 -烷酮衍生物及其作為 抑制劑的用途 HK1158631A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803299A FR2932482B1 (fr) 2008-06-13 2008-06-13 Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
PCT/FR2009/051118 WO2009150388A1 (fr) 2008-06-13 2009-06-12 NOUVEAUX DERIVES DE (PIPERAZINYL PONTE)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75

Publications (1)

Publication Number Publication Date
HK1158631A1 true HK1158631A1 (zh) 2012-07-20

Family

ID=40305395

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11112930.5A HK1158631A1 (zh) 2008-06-13 2011-11-29 橋接的哌嗪基 -烷酮衍生物及其作為 抑制劑的用途

Country Status (39)

Country Link
US (2) US8193190B2 (zh)
EP (1) EP2297148B8 (zh)
JP (1) JP5476373B2 (zh)
KR (1) KR101642526B1 (zh)
CN (1) CN102124006B (zh)
AR (1) AR072103A1 (zh)
AT (1) ATE540039T1 (zh)
AU (1) AU2009259121B2 (zh)
BR (1) BRPI0915126B8 (zh)
CA (1) CA2727669C (zh)
CL (1) CL2010001429A1 (zh)
CO (1) CO6280535A2 (zh)
CR (1) CR11832A (zh)
CY (1) CY1112610T1 (zh)
DK (1) DK2297148T3 (zh)
DO (2) DOP2010000380A (zh)
EA (1) EA019074B1 (zh)
EC (1) ECSP10010672A (zh)
ES (1) ES2379685T3 (zh)
FR (1) FR2932482B1 (zh)
HK (1) HK1158631A1 (zh)
HR (1) HRP20120290T1 (zh)
IL (1) IL209902A (zh)
JO (1) JO2774B1 (zh)
MA (1) MA32474B1 (zh)
MX (1) MX2010013695A (zh)
MY (1) MY150988A (zh)
NI (1) NI201000215A (zh)
NZ (1) NZ589840A (zh)
PE (1) PE20110154A1 (zh)
PL (1) PL2297148T3 (zh)
PT (1) PT2297148E (zh)
RS (1) RS52262B (zh)
SI (1) SI2297148T1 (zh)
SV (1) SV2010003755A (zh)
TW (1) TWI432433B (zh)
UA (1) UA101979C2 (zh)
UY (1) UY31893A (zh)
WO (1) WO2009150388A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931223B1 (fr) 2008-05-16 2010-08-20 Air Liquide Dispositif distributeur de gaz sous pression, ensemble comprenant un tel dispositif et dispositif de commande, recipient pourvu d'un tel dispositif distributeur
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3236243A1 (de) * 1982-09-30 1984-04-05 Merck Patent Gmbh, 6100 Darmstadt Schwefelhaltige indolderivate
FR2744448B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) * 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
AU4198400A (en) 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
PT2297148E (pt) 2012-04-03
DOP2010000380A (es) 2011-01-15
CR11832A (es) 2011-02-04
NI201000215A (es) 2011-05-04
HRP20120290T1 (hr) 2012-04-30
CO6280535A2 (es) 2011-05-20
EP2297148B8 (fr) 2012-03-28
US8193190B2 (en) 2012-06-05
EP2297148A1 (fr) 2011-03-23
TW201002710A (en) 2010-01-16
UY31893A (es) 2010-01-29
EA019074B1 (ru) 2013-12-30
DOP2013000124A (es) 2013-12-31
EA201170016A1 (ru) 2011-08-30
PL2297148T3 (pl) 2012-05-31
NZ589840A (en) 2012-11-30
US20110144116A1 (en) 2011-06-16
AU2009259121B2 (en) 2013-12-19
RS52262B (en) 2012-10-31
MA32474B1 (fr) 2011-07-03
BRPI0915126A2 (pt) 2016-02-16
FR2932482A1 (fr) 2009-12-18
KR101642526B1 (ko) 2016-07-25
TWI432433B (zh) 2014-04-01
JP5476373B2 (ja) 2014-04-23
SI2297148T1 (sl) 2012-05-31
CA2727669C (fr) 2016-08-23
BRPI0915126B8 (pt) 2021-05-25
DK2297148T3 (da) 2012-05-07
EP2297148B1 (fr) 2012-01-04
KR20110018435A (ko) 2011-02-23
SV2010003755A (es) 2011-03-15
JP2011522869A (ja) 2011-08-04
IL209902A0 (en) 2011-02-28
IL209902A (en) 2014-09-30
PE20110154A1 (es) 2011-03-14
AU2009259121A1 (en) 2009-12-17
MY150988A (en) 2014-03-31
MX2010013695A (es) 2011-03-04
WO2009150388A1 (fr) 2009-12-17
UA101979C2 (ru) 2013-05-27
CN102124006B (zh) 2014-06-11
CL2010001429A1 (es) 2011-07-29
AR072103A1 (es) 2010-08-04
ATE540039T1 (de) 2012-01-15
ES2379685T3 (es) 2012-04-30
BRPI0915126B1 (pt) 2019-09-24
CY1112610T1 (el) 2016-02-10
US8519143B2 (en) 2013-08-27
US20120232280A1 (en) 2012-09-13
CA2727669A1 (fr) 2009-12-17
ECSP10010672A (es) 2011-01-31
FR2932482B1 (fr) 2010-10-08
CN102124006A (zh) 2011-07-13
JO2774B1 (en) 2014-03-15

Similar Documents

Publication Publication Date Title
HK1254895A1 (zh) 苄基苯衍生物及使用方法
HK1157751A1 (zh) 橋連雜環化合物及其使用方法
HK1160119A1 (zh) 激酶抑制劑及其使用方法
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
HK1162352A1 (zh) 某些犬尿氨酸- -單加氧酶抑制劑、藥物組合物以及使用方法
IL213596A0 (en) Heterocyclic compounds and methods of use
EP2480081A4 (en) Bridged heterocyclic compounds and methods for their use
ZA201004670B (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
EP2262754A4 (en) MINOCYCLINE COMPOUNDS AND METHODS OF USE THEREOF
ZA200906062B (en) Benzimidazole derivatives and methods of use thereof
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
IL208403A0 (en) Compositions and use of epas1 inhibitors
IL216883A0 (en) Diazahomoadamantane derivatives and methods of use thereof
ZA201007129B (en) Limk2 inhibitors,compositions comprising them,and methods of their use
EP2134352A4 (en) WNT COMPOSITIONS AND METHODS FOR THEIR USE
ZA201008609B (en) Heterocyclic urea derivatives and methods of use thereof
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
HK1158631A1 (zh) 橋接的哌嗪基 -烷酮衍生物及其作為 抑制劑的用途
EP2126056A4 (en) INHIBITORS OF THE PARAMYXOVIRUS FAMILY AND METHODS OF USE THEREOF
IL219935A0 (en) Small pyrimidine derivatives and methods of use thereof
ZA201204339B (en) Novel (heterocycle-tetrahydropyridine)(piperazinyl)-1-alcanone and (heterocycle-dihydropyrrolidine)(piperazinyl)-1-alcanone derivatives,and use thereof as p75 inhibitors
EP2344454A4 (en) ANTIOXIDATION COMPOUNDS AND METHOD FOR THEIR USE
ZA201002885B (en) Quinoline derivatives and their use as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180612